TARRYTOWN, New York, August 25 /PRNewswire/ --

- Replace Expired Plans Initially Adopted in 2006

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today that on August 22, 2007 TVM III Limited Partnership ("TVM III"), TVM IV
GmbH & Co. KG ("TVM IV") and Mr. John J. DiBello each entered into trading
plans with Deutsche Bank Securities Inc. pursuant to Rule 10b5-1 of the
Exchange Act of 1934. The Plans follow the recent expiration of similar plans
that were adopted in June 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Dr. Gert Caspritz, a director of the Company, is a General Partner and an
Investment Manager in the healthcare and life sciences group of TVM Capital,
which is the general partner of each of TVM III and TVM IV. In addition, Mr.
John J. DiBello is an affiliate of the Company and a Partner of TVM Capital.
Under these trading plans, the Company's stock price must reach a minimum of
US$4.00 per share before any of TVM III's, TVM IV's or Mr. DiBello's shares
may be sold. Under these plans, each 10b5-1 plan shareholder has authorized
the sale of up to the full amount of their holdings of EpiCept common stock.

Under the plans, the 10b5-1 shareholders may sell 25% of their individual
holdings at a price range of US$4.00 to US$6.49 per share, 25% of their
individual holdings at a price range of US$6.50 to US$8.99 per share, an
additional 25% of their individual holdings at a price range of US$9.00 to
US$11.49 per share, and the final 25% of their individual holdings at a price
at or above US$11.50 per share. Sales under the plans may begin on August 22,
2007, and the plans are scheduled to continue for 12 months from the date of
inception.

The plans also provide that the shares are to be sold pro-rata as allowed
pursuant to Rule 144 of the Securities Act of 1933. The common stock sales
will occur from time to time in accordance with the trading plans and will be
conducted under the direction of Deutsche Bank Securities Inc. TVM III, TVM
IV and Mr. DiBello will report the sales as appropriate in filings with the
Securities and Exchange Commission as required by law.

In order to maintain compliance with the rules of the OMX Nordic Stock
Exchange (where, in addition to Nasdaq, the Company's securities are listed
under the ticker symbol: EPCT), the plans provide that no trading shall take
place during the 30-day period prior to the release of financial statements
for the prior quarter, resulting in the following restricted periods:
September 17, 2007 - November 16, 2007, December 18, 2007 - May 19, 2008, and
June 17, 2008 - August 18, 2008; provided that the end of each restricted
period shall be extended to the date of the actual public announcement of the
Company's results or such later date as required by the OMX Nordic Exchange.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer.
EpiCept has a staged portfolio of pharmaceutical product candidates with
several pain therapies in late-stage clinical trials, and a lead oncology
compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a
Phase III trial; a marketing authorization application for this compound has
been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its
research and development team in San Diego is pursuing a drug discovery
program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the
information contained in this news release, contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements which express
plans, anticipation, intent, contingency, goals, targets, future development
and are otherwise not statements of historical fact. These statements are
based on EpiCept's current expectations and are subject to risks and
uncertainties that could cause actual results or developments to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Factors that may
cause actual results or developments to differ materially include: the risk
that Ceplene will not receive regulatory approval or marketing authorization
in the EU or that Ceplene, if approved, will not achieve significant
commercial success, the risk that Myriad's development of Azixa will not be
successful, the risk that Azixa will not receive regulatory approval or
achieve significant commercial success, the risk that we will not receive any
significant payments under our agreement with Myriad, the risk that the
development of our other apoptosis product candidates will not be successful,
the risk that our ASAP technology will not yield any successful product
candidates, the risk that clinical trials for NP-1 will not be successful,
that NP-1 will not receive regulatory approval or achieve significant
commercial success, the risk that our other product candidates that appeared
promising in early research and clinical trials do not demonstrate safety
and/or efficacy in larger-scale or later stage clinical trials, the risk that
EpiCept will not obtain approval to market any of its product candidates, the
risks associated with reliance on additional outside financing to meet its
capital requirements, the risks associated with dependence upon key
personnel, the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product development,
clinical trials and regulatory approval process; our history of operating
losses since our inception; competition; litigation; risks associated with
prior material weaknesses in our internal controls; and risks associated with
our ability to protect our intellectual property. These factors and other
material risks are more fully discussed in EpiCept's periodic reports,
including its reports on Forms 8-K, 10-Q and 10-K and other filings with the
U.S. Securities and Exchange Commission. You are urged to carefully review
and consider the disclosures found in EpiCept's filings which are available
at www.sec.gov or at www.epicept.com. You are cautioned not to place undue
reliance on any forward-looking statements, any of which could turn out to be
wrong due to inaccurate assumptions, unknown risks or uncertainties or other
risk factors.

EPCT-GEN

Web site: http://www.epicept.com